Clinical Trials Logo

Clinical Trial Summary

the study evaluate the efficacy and safety of EUS-RFA using Habib EUS-RFA catheter with a prospective randomised trial in patients with inoperable PDAC.


Clinical Trial Description

The five year survival for pancreatic ductal adenocarcinoma (PDAC) is less than 5% in spite of the advances in management of cancers in the last few decades. Endobiliary application of radiofrequency ablation (RFA) has been developed in our unit and used in patients with unresectable bile duct and pancreatic head adenocarcinomas presenting with biliary obstruction. Various techniques of EUS-guided tumour ablation have been described, including RF ablation, photodynamic therapy, laser ablation, and ethanol injection. Endoscopic ultrasound guided RFA (EUS-RFA) of the pancreatic head using Habib EUS-RFA catheter through a 19-gauge needle was well tolerated in 5 Yucatan pigs and with minimum amount of pancreatitis . ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03772756
Study type Interventional
Source First People's Hospital of Hangzhou
Contact
Status Completed
Phase N/A
Start date December 20, 2018
Completion date August 16, 2021

See also
  Status Clinical Trial Phase
Completed NCT02336672 - EUS-Guided Cryothermal Ablation in Patients With Stage III Pancreatic Adenocarcinoma (HybridTherm Study) N/A
Active, not recruiting NCT04395469 - FAZA PET/MRI Pancreas N/A
Recruiting NCT05524090 - PREOPANC-4 Implementation Program for Locally Advanced Pancreatic Cancer
Terminated NCT02910882 - PEGPH20 Plus Gemcitabine With Radiotherapy in Patients With Localized, Unresectable Pancreatic Cancer Phase 2
Completed NCT01677962 - A Study of Vaccination With Poly-ICLC and Dendritic Cells in Patients With Pancreatic Adenocarcinoma Phase 1
Completed NCT01053013 - Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic/Colorectal Cancer Phase 2